Accessing neuroinflammation sites: Monocyte/neutrophil-mediated drug delivery for cerebral ischemia
Citations Over TimeTop 10% of 2019 papers
Abstract
Cerebral ischemia (CI) results from inadequate blood flow to the brain. The difficulty of delivering therapeutic molecules to lesions resulting from CI hinders the effective treatment of this disease. The inflammatory response following CI offers a unique opportunity for drug delivery to the ischemic brain and targeted cells because of the recruitment of leukocytes to the stroke core and penumbra. In the present study, neutrophils and monocytes were explored as cell carriers after selectively carrying cRGD liposomes, which effectively transmigrated the blood-brain barrier, infiltrated the cerebral parenchyma, and delivered therapeutic molecules to the injured sites and target cells. Our results showed the successful comigration of liposomes with neutrophils/monocytes and that both monocytes and neutrophils were important for successful delivery. Enhanced protection against ischemic injury was achieved in the CI/reperfusion model. The strategy presented here shows potential in the treatment of CI and other diseases related to inflammation.
Related Papers
- → Role of Neuroinflammation in the Trajectory of Alzheimer’s Disease and in vivo Quantification Using PET(2018)61 cited
- → "Lipopolysaccharide-induced animal models for neuroinflammation – An overview."(2023)57 cited
- → Insights into the advances in therapeutic drugs for neuroinflammation-related diseases(2023)7 cited
- → Neuroinflammation and oxidative injury in developmental neurotoxicity(2011)13 cited
- → Characterisation of ReNcells CX and VM stimulated with interleukin-1β and lipopolysaccharide(2022)4 cited